Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC-TR-128-B07, CRC-TR-128-Z2)
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (KuT3/007/20)
National Multiple Sclerosis Society (RFA-2202-39141)
Universitätsklinikum Münster
Article History
Received: 14 April 2023
Revised: 5 October 2023
Accepted: 5 October 2023
First Online: 28 October 2023
Declarations
:
: TK received research funding from the German Research Foundation, Interdisciplinary Center for Clinical Research (IZKF) Münster, National MS Society, Progressive MS Alliance, European Commission (H2020-MSCA-ITN-2018), and Novartis. She received compensation for serving on scientific advisory boards (Novartis) and speaker honoraria from Novartis, Biogen, and Roche.